Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,232.59 +209.91 (+0.32%) CMC Crypto 200
1,375.25 -42.62 (-3.01%)
SCLX Jun 2024 4.000 put
| Previous close | 2.1700 |
| Open | 2.1700 |
| Bid | 0.8000 |
| Ask | 4.2000 |
| Strike | 4.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.1700 - 2.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireScilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of Pain, and features original research on the nature, mechanisms and treatment of pain.This Phase 3 study met primary and important key secondary endpoints, with SP-102 (SEMDEXA™) treatment, decreasing pain intensity for over a month in sciatica patients and resulting in statistically signi
Simply Wall St.Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Scilex Holding Company ( NASDAQ:SCLX ) - they aren't optimistic, having...
- GlobeNewswire
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results from a post-hoc analysis of two Phase 3 randomized clinical trials.In patients who had an insufficient response to triptans, significantly more patients in the ELYXYB®-treated arm achieved 2-hour pain freedom (the gold standard for efficacy endpoint in migraine) than placebo (33.3
